Repligen Announces Publication of the Company’s 2023 Corporate Sustainability Report
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Repligen (NASDAQ:RGEN) has published its 2023 Corporate Sustainability Report, titled 'Advancing Impacts.' The report outlines progress across six key impact areas: Products & Packaging, Operations, Talent, Supply Chain, Communities, and Partnerships & Pathways.
Key achievements include:
- Expansion of 100% renewable electricity to 13 of 18 manufacturing sites (88% of global consumption)
- Increase in women in management positions from 27% to 29%
- 68% reduction in Scope 2 emissions from 2022 to 2023
- 60% increase in productivity savings through Repligen Performance System
- Commitment to net-zero emissions by 2050 with Science Based Targets initiative
The report aligns with major reporting frameworks including GRI Standards, SASB, UN SDGs, and TCFD, and serves as Repligen's 2023 Communication on Progress for the UN Global Compact.
Details
News Market Reaction – RGEN
The recorded move for RGEN in the trading session of this news was +0.48%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2023 Corporate Sustainability Report and related reporting framework disclosures. Themed “Advancing Impacts”, this newly reformatted report streamlines the company’s progress in advancing our sustainability strategy across six key impact areas: Products & Packaging, Operations, Talent, Supply Chain, Communities and Partnerships & Pathways. Also included in the 2023 Sustainability Report are detailed disclosures aligned with four key reporting frameworks: the Global Reporting Initiative (GRI) Standards, Sustainability Accounting Standards Board (SASB), United Nations Sustainable Development Goals (UN SDGs) and Task Force on Climate-Related Disclosures (TCFD).
Olivier Loeillot, President and Chief Executive Officer at Repligen said, “I am delighted with the progress we’ve made on key sustainability metrics and am pleased to share the positive impacts highlighted in this ambitious annual report. I look forward to continuing to support these important initiatives that reflect our commitment to responsible corporate citizenship.”
Dianne Heiler, Vice President of Sustainability and Global Head of Packaging Engineering at Repligen said, “I’m especially proud to have led the development of this reformatted report and to have submitted our commitment letter to SBTi to lower total GHG emissions in alignment with the latest climate science. This publication also serves as Repligen’s Corporation’s 2023 Communication on Progress in fulfillment of our annual commitment to the UNGC (United Nations Global Compact).”
Below are just a few of the 2023 Sustainability Report highlights across environmental, social and governance topics. Report data is through year end 2023 unless otherwise noted.
Advancing Impacts: Report Highlights
- Expanded our transition to
100% renewable electricity from 9 to 13 of 18 manufacturing sites, representing88% of our global consumption. - Increased the percentage of women in management, defined as Associate Director and above, from
27% in 2022 to29% in 2023. - Reduced Scope 2 emissions by
68% from 2022 to 2023. - Achieved a
60% increase in productivity savings through the Repligen Performance System (RPS) compared to 2022. - Committed to net-zero emissions by 2050 with the Science Based Targets initiative (SBTi).
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information, please visit www.repligen.com, and follow us on LinkedIn.
Forward Looking Statements
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.
Repligen Contact:
Sondra S. Newman
VP, Global Head of Investor Relations
(781) 419-1881
investors@repligen.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.